Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Loeffler, M' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 80 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Meineke, FA; Potten, CS; Loeffler, M
      Cell migration and organization in the intestinal crypt using a lattice-free model

      CELL PROLIFERATION
    2. Loeffler, M; Shipp, M; Stein, H
      2. Report on the Workshop: "Clinical consequences of pathology and prognostic factors in aggressive NHL"

      ANNALS OF HEMATOLOGY
    3. Hasenclever, D; Loeffler, M
      Five theses concerning the clinical consequences of pathology and prognostic factors

      ANNALS OF HEMATOLOGY
    4. Rube, C; Nguyen, TP; Kloss, M; Loeffler, M; Trumper, L; Pfreundschuh, M
      Consolidation radiotherapy to bulky disease in aggressive NHL. First results of the NHL B-94 trial of the DSHNHL

      ANNALS OF HEMATOLOGY
    5. Hasenclever, D; Brosteanu, O; Gerike, T; Loeffler, M
      Modelling of chemotherapy: The effective dose approach

      ANNALS OF HEMATOLOGY
    6. Pfreundschuh, M; Hasenclever, D; Loeffler, M; Ehninger, G; Schmitz, N; Kirchner, H; Koch, P; Lathan, B; Rueffer, U; Sextro, M; Franklin, J; Tesch, H; Diehl, V
      Dose escalation of cytotoxic drugs using haematopoietic growth factors: A randomized trial to determine the magnitude of increase provided by GM-CSF

      ANNALS OF ONCOLOGY
    7. Loeffler, M; Daugas, E; Susin, SA; Zamzami, N; Metivier, D; Nieminen, AL; Brothers, G; Penninger, JM; Kroemer, G
      Dominant cell death induction by extramitochondrially targeted apoptosis-inducing factor

      FASEB JOURNAL
    8. Duhmke, E; Franklin, J; Pfreundschuh, M; Sehlen, S; Willich, N; Ruhl, U; Muller, RP; Lukas, P; Atzinger, A; Paulus, U; Lathan, B; Ruffer, U; Sieber, M; Wolf, J; Engert, A; Georgii, A; Staar, S; Herrmann, R; Beykirch, M; Kirchner, H; Emminger, A; Greil, R; Fritsch, E; Koch, P; Drochtert, A; Brosteanu, O; Hasenclever, D; Loeffler, M; Diehl, V
      Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: Long-term results of a randomized trial of radiotherapy alone

      JOURNAL OF CLINICAL ONCOLOGY
    9. Drasdo, D; Loeffler, M
      Individual-based models to growth and folding in one-layered tissues: Intestinal crypts and early development

      NONLINEAR ANALYSIS-THEORY METHODS & APPLICATIONS
    10. Kaltenhauser, S; Wagner, U; Schuster, E; Wassmuth, R; Arnold, S; Seidel, W; Troltzsch, M; Loeffler, M; Hantzschel, H
      Immunogenetic markers and seropositivity predict radiological progression in early rheumatoid arthritis independent of disease activity

      JOURNAL OF RHEUMATOLOGY
    11. Jacotot, E; Ferri, KF; El Hamel, C; Brenner, C; Druillennec, S; Hoebeke, J; Rustin, P; Metivier, D; Lenoir, C; Geuskens, M; Vieira, HLA; Loeffler, M; Belzacq, AS; Briand, JP; Zamzami, N; Edelman, L; Xie, ZH; Reed, JC; Roques, BP; Kroemer, G
      Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein R and Bcl-2

      JOURNAL OF EXPERIMENTAL MEDICINE
    12. Dallaporta, B; de Pablo, M; Maisse, C; Daugas, E; Loeffler, M; Zamzami, N; Kroemer, G
      Proteasome activation as a critical event of thymocyte apoptosis

      CELL DEATH AND DIFFERENTIATION
    13. Potten, CS; Barthel, D; Li, YQ; Ohlrich, R; Matthe, B; Loeffler, M
      Proliferation in murine epidermis after minor mechanical stimulation - Part 1. Sustained increase in keratinocyte production and migration

      CELL PROLIFERATION
    14. Barthel, D; Matthe, B; Potten, CS; Owen, G; Loeffler, M
      Proliferation in murine epidermis after minor mechanical stimulation - 2. Alterations in keratinocyte cell cycle fluxes

      CELL PROLIFERATION
    15. Zamzami, N; El Hamel, C; Maisse, C; Brenner, C; Munoz-Pinedo, C; Belzacq, AS; Costantini, P; Vieira, H; Loeffler, M; Molle, G; Kroemer, G
      Bid acts on the permeability transition pore complex to induce apoptosis

      ONCOGENE
    16. Engel, C; Loeffler, M; Schmitz, S; Tesch, H; Diehl, V
      Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease

      ANNALS OF ONCOLOGY
    17. Volkmer, BG; Kuefer, R; Nesslauer, T; Loeffler, M; Gottfried, HW
      Colour Doppler ultrasound in vesicovaginal fistulas

      ULTRASOUND IN MEDICINE AND BIOLOGY
    18. Susin, SA; Daugas, E; Ravagnan, L; Samejima, K; Zamzami, N; Loeffler, M; Costantini, P; Ferri, KF; Irinopoulou, T; Prevost, MC; Brothers, G; Mak, TW; Penninger, J; Earnshaw, WC; Kroemer, G
      Two distinct pathways leading to nuclear apoptosis

      JOURNAL OF EXPERIMENTAL MEDICINE
    19. Jacotot, E; Ravagnan, L; Loeffler, M; Ferri, KF; Vieira, HLA; Zamzami, N; Costantini, P; Druillennec, S; Hoebeke, J; Briand, JP; Irinopoulou, T; Daugas, E; Susin, SA; Cointe, D; Xie, ZH; Reed, JC; Roques, BP; Kroemer, G
      The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore

      JOURNAL OF EXPERIMENTAL MEDICINE
    20. Daugas, E; Nochy, D; Ravagnan, L; Loeffler, M; Susin, SA; Zamzami, N; Kroemer, G
      Apoptosis-inducing factor (AIF): a ubiquitous mitochondrial oxidoreductaseinvolved in apoptosis

      FEBS LETTERS
    21. Loeffler, M; Kroemer, G
      The mitochondrion in cell death control: Certainties and incognita

      EXPERIMENTAL CELL RESEARCH
    22. Mantovani, L; Lentini, C; Hentschel, B; Wickramanayake, PD; Loeffler, M; Diehl, V; Tesch, H
      Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin

      BRITISH JOURNAL OF HAEMATOLOGY
    23. Shipp, MA; Abeloff, MD; Antman, KH; Carroll, G; Hagenbeek, A; Loeffler, M; Montserrat, E; Radford, JA; Salles, G; Schmitz, N; Symann, M; Armitage, JO; Coiffier, B; Philip, T
      International Consensus Conference on High-Dose Therapy with HematopoieticStem-Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: Report ofjury

      ANNALS OF ONCOLOGY
    24. Loeffler, M; Brosteanu, O; Hasenclever, D
      MOPP versus ABVD and low-dose versus high-dose irradiation in Hodgkin's disease at intermediate and advanced stages: Analysis of a meta-analysis by clinicians - In reply

      JOURNAL OF CLINICAL ONCOLOGY
    25. Shipp, MA; Abeloff, MD; Antman, KH; Carroll, G; Hagenbeek, A; Loeffler, M; Montserrat, E; Radford, JA; Salles, G; Schmitz, N; Symann, M; Armitage, JO; Philip, T; Coiffier, B
      International consensus conference on high-dose therapy with hematopoieticstem cell transplantation in aggressive non-hodgkin's lymphomas: Report ofthe jury

      JOURNAL OF CLINICAL ONCOLOGY
    26. Susin, SA; Lorenzo, HK; Zamzami, N; Marzo, I; Snow, BE; Brothers, GM; Mangion, J; Jacotot, E; Costantini, P; Loeffler, M; Larochette, N; Goodlett, DR; Aebersold, R; Siderovski, DP; Penninger, JM; Kroemer, G
      Molecular characterization of mitochondrial apoptosis-inducing factor

      NATURE
    27. Engel, C; Loeffler, M; Franke, H; Schmitz, S
      Endogenous thrombopoietin serum levels during multicycle chemotherapy

      BRITISH JOURNAL OF HAEMATOLOGY
    28. Loeffler, M; Henry-Amar, M; Somers, R
      Contributions of the international database on Hodgkin's disease

      HODGKIN'S DISEASE
    29. GERIKE TG; PAULUS U; POTTEN CS; LOEFFLER M
      A DYNAMIC-MODEL OF PROLIFERATION AND DIFFERENTIATION IN THE INTESTINAL CRYPT BASED ON A HYPOTHETICAL INTRAEPITHELIAL GROWTH-FACTOR

      Cell proliferation
    30. Diehl, V; Franklin, J; Hasenclever, D; Tesch, H; Pfreundschuh, M; Lathan, B; Paulus, U; Sieber, M; Ruffer, JU; Sextro, M; Engert, A; Wolf, J; Hermann, R; Holmer, L; Stappert-Jahn, U; Winnerlein-Trump, E; Wulf, G; Krause, S; Glunz, A; von Kalle, K; Bischoff, H; Haedicke, C; Duhmke, E; Georgii, A; Loeffler, M
      BEACOPP: A new regimen for advanced Hodgkin's disease

      ANNALS OF ONCOLOGY
    31. Loeffler, M; Hasenclever, D; Diehl, V
      Model based development of the BEACOPP regimen for advanced stage Hodgkin's disease

      ANNALS OF ONCOLOGY
    32. LOEFFLER M; BROSTEANU O; HASENCLEVER D
      COMBINED-MODALITY IN ADVANCED HODGKINS-DISEASE - REPLY

      Journal of clinical oncology
    33. LOEFFLER M; BROSTEANU O; HASENCLEVER D; SEXTRO M; ASSOULINE D; BARTOLUCCI AA; CASSILETH PA; CROWTHER D; DIEHL V; FISHER RI; HOPPE RT; JACOBS P; PATER JL; PAVLOVSKY S; THOMPSON E; WIERNIK P
      METAANALYSIS OF CHEMOTHERAPY VERSUS COMBINED-MODALITY TREATMENT TRIALS IN HODGKINS-DISEASE

      Journal of clinical oncology
    34. Diehl, V; Franklin, J; Hasenclever, D; Tesch, H; Pfreundschuh, M; Lathan, B; Paulus, U; Sieber, M; Rueffer, JU; Sextro, M; Engert, A; Wolf, J; Hermann, R; Holmer, L; Stappert-Jahn, U; Winnerlein-Trump, E; Wulf, G; Krause, S; Glunz, A; von Kalle, K; Bischoff, H; Haedicke, C; Duehmke, E; Georgii, A; Loeffler, M
      BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's Lymphoma Study Group

      JOURNAL OF CLINICAL ONCOLOGY
    35. STUMPP P; FRANKE H; ENGEL C; SCHMITZ S; LOEFFLER M
      MODEL-BASED OPTIMIZATION OF G-CSF SCHEDULING IN MULTICYCLE CHEMOTHERAPY

      Experimental hematology
    36. GEBAUER C; ENGEL C; WILKENS M; NIJHOF W; LOEFFLER M
      LINEAGE INTERACTIONS DURING PROLONGED COMBINED ADMINISTRATION OF EPO AND G-CSF EXPLAINED BY A COMPREHENSIVE MODEL OF MURINE ERYTHRO-POIESISAND GRANULOPOIESIS

      Experimental hematology
    37. ROEDER I; LOEFFLER M
      MODELING THE CLONAL DYNAMICS OF PRIMITIVE HEMATOPOIESIS IN-VIVO

      Experimental hematology
    38. ENGEL C; WIESNER T; SCHMITZ S; LOEFFLER M
      ENDOGENOUS SERUM LEVELS OF THROMBOPOIETIN DURING MULTIPLE CYCLES OF CHEMOTHERAPY

      Experimental hematology
    39. TSODIKOV A; HASENCLEVER D; LOEFFLER M
      REGRESSION WITH BOUNDED OUTCOME SCORE - EVALUATION OF POWER BY BOOTSTRAP AND SIMULATION IN A CHRONIC MYELOGENOUS LEUKEMIA CLINICAL-TRIAL

      Statistics in medicine
    40. TSODIKOV A; LOEFFLER M; YAKOVLEV A
      A CURE MODEL WITH TIME-CHANGING RISK FACTOR - AN APPLICATION TO THE ANALYSIS OF SECONDARY LEUKEMIA - A REPORT FROM THE INTERNATIONAL DATABASE ON HODGKINS-DISEASE

      Statistics in medicine
    41. ROEDER I; DEHAAN G; ENGEL C; NIJHOF W; DONTJE B; LOEFFLER M
      INTERACTIONS OF ERYTHROPOIETIN, GRANULOCYTE-COLONY-STIMULATING FACTOR, STEM-CELL FACTOR, AND INTERLEUKIN-11 ON MURINE HEMATOPOIESIS DURING SIMULTANEOUS ADMINISTRATION

      Blood
    42. Tesch, H; Diehl, V; Lathan, B; Hasenclever, D; Sieber, M; Ruffer, U; Engert, A; Franklin, J; Pfreundschuh, M; Schalk, KP; Schwieder, G; Wulf, G; Dolken, G; Worst, P; Koch, P; Schmitz, N; Bruntsch, U; Tirier, C; Muller, U; Loeffler, M
      Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: A study of the German Hodgkin's Lymphoma Study Group

      BLOOD
    43. DIEHL V; SIEBER M; RUFFER U; LATHAN B; HASENCLEVER D; PFREUNDSCHUH M; LOEFFLER M; LIEBERZ D; KOCH P; ADLER M; TESCH H
      BEACOPP - AN INTENSIFIED CHEMOTHERAPY REGIMEN IN ADVANCED HODGKINS-DISEASE

      Annals of oncology
    44. LOEFFLER M; DIEHL V; PFREUNDSCHUH M; RUHL U; HASENCLEVER D; NISTERSBACKES H; SIEBER M; TESCH H; FRANKLIN J; GEILEN W; BARTELS H; CARTONI C; DOLKEN G; ENZIAN J; FUCHS R; GASSMANN W; GERHARTZ H; HAGENAUKAMP U; HILLER E; HINKELBEIN H; HINTERBERGER W; KIRCHNER H; KOCH P; KRUGER B; KURTEN H; KUTZNER K; LOOS U; MENDE W; MULLER H; OERTEL W; PETSCH S; PFAB R; PFLUGER H; ROHLOFF R; SAUER R; SCHALK K; SCHICK HD; SCHOPPE W; SZEPESI S; TEICHMANN J; WORST P; FISCHER R; GEORGII A; HUBNER K; SCHWARZE EW
      DOSE-RESPONSE RELATIONSHIP OF COMPLEMENTARY RADIOTHERAPY FOLLOWING 4 CYCLES OF COMBINATION CHEMOTHERAPY IN INTERMEDIATE-STAGE HODGKINS-DISEASE

      Journal of clinical oncology
    45. FRANKE H; ENGEL C; LOEFFLER M; DIEHL V; SCHMITZ S
      DOSE INTENSIFICATION OF CHEMOTHERAPY - AN ESTIMATION OF HEMATOLOGICALTOXICITY AND THE EFFECT OF DIFFERENT G-CSF ADMINISTRATION BY MODEL SIMULATION

      Experimental hematology
    46. KLIEM C; FORBERG J; SCHOEMPERLEN J; LOEFFLER M
      A MATHEMATICAL-MODEL OF THROMBOPOIESIS IN MICE

      Experimental hematology
    47. LOEFFLER M; BRATKE T; PAULUS U; LI YQ; POTTEN CS
      CLONALITY AND LIFE-CYCLES OF INTESTINAL CRYPTS EXPLAINED BY A STATE-DEPENDENT STOCHASTIC-MODEL OF EPITHELIAL STEM-CELL ORGANIZATION

      Journal of theoretical biology
    48. SIEBER M; RUEFFER U; TESCH H; LIEBERZ D; PAULUS U; BROSTEANU O; LOEFFLER M; PFREUNDSCHUH M; LATHAN B; DUHMKE E; GEORGII A; HILLER E; KOCH P; DOLKEN G; CERNY T; CARTONI C; MANDELLI F; DIEHL V
      RAPIDLY ALTERNATING COPP PLUS ABV PLUS IMEP (CAI) IS EQUALLY EFFECTIVE AS ALTERNATING COPP PLUS ABVD (CA) FOR HODGKINS-DISEASE - FINAL RESULTS OF 2 RANDOMIZED TRIALS FOR INTERMEDIATE (HD5 PROTOCOL) AND ADVANCED (HD6 PROTOCOL) STAGES

      Blood
    49. HASENCLEVER D; LOEFFLER M; DIEHL V
      RATIONALE FOR DOSE-ESCALATION OF FIRST LINE CONVENTIONAL CHEMOTHERAPYIN ADVANCED HODGKINS-DISEASE

      Annals of oncology
    50. DUHMKE E; DIEHL V; LOEFFLER M; MUELLER RP; RUEHL U; WILLICH N; GEORGII A; ROTH S; MATTHAEI D; SEHLEN S; BROSTEANU O; HASENCLEVER D; WILKOWSKI R; BECKER K
      RANDOMIZED TRIAL WITH EARLY-STAGE HODGKINS-DISEASE TESTING 30 GY VS 40 GY EXTENDED FIELD RADIOTHERAPY ALONE

      International journal of radiation oncology, biology, physics
    51. SCHMITZ S; FRANKE H; LOEFFLER M; WICHMANN HE; DIEHL V
      MODEL ANALYSIS OF THE CONTRASTING EFFECTS OF GM-CSF AND G-CSF TREATMENT ON PERIPHERAL-BLOOD NEUTROPHILS OBSERVED IN 3 PATIENTS WITH CHILDHOOD-ONSET CYCLIC NEUTROPENIA

      British Journal of Haematology
    52. TESCH H; PAULUS U; HASENCLEVER D; LIEBERZ D; SEXTRO M; SIEBER M; RUEFFER U; ENGERT A; KOCH T; DUEHMKE E; GEORGII A; LOEFFLER M; PFREUNDSCHUH M; DIEHL V
      STAGE IVB AND ANEMIA ARE POOR PROGNOSTIC FACTORS IN ADVANCED STAGES OF HODGKINS-DISEASE - RESULTS OF THE HD6 STUDY OF THE GHSG

      Blood
    53. LOEFFLER M; BROSTEANU O; HASENCLEVER D; SEXTRO M; COSSET J; DAHLBERG S; FISHER R; GRAY R; HENRYAMAR M; HOPPE R; SOMERS R; SPECHT L
      COMBINED-MODALITY TREATMENT VS CHEMOTHERAPY ALONE IN HODGKINS-DISEASE(HD) - AN OVERVIEW ON RANDOMIZED TRIALS

      Blood
    54. TESCH H; PAULUS U; HASENCLEVER D; LIEBERZ D; SEXTRO M; SIEBER M; RUEFFER U; ENGERT A; KOCH T; DUEHMKE E; GEORGII A; LOEFFLER M; PFREUNDSCHUH M; DIEHL V
      THE RAPIDLY ALTERNATING SCHEME COPP-ABV-IMEP IS EQUALLY EFFECTIVE AS COPP-ABVD IN ADVANCED STAGES OF HODGKINS-DISEASE - RESULTS OF THE HD6 STUDY OF THE GHSG

      Blood
    55. DEHAAN G; DONTJE B; ENGEL C; LOEFFLER M; NIJHOF W
      PROPHYLACTIC PRETREATMENT OF MICE WITH HEMATOPOIETIC GROWTH-FACTORS INDUCES EXPANSION OF PRIMITIVE CELL COMPARTMENTS AND RESULTS IN PROTECTION AGAINST 5-FLUOROURACIL-INDUCED TOXICITY

      Blood
    56. KALTENHAEUSER S; SEIDEL W; WAGNER U; BAER I; SCHUSTER E; LOEFFLER M; HAENTZSCHEL H
      PROGNOSTIC FACTORS INFLUENCING THE CLINICAL COURSE OF RECENT-ONSET RHEUMATOID-ARTHRITIS

      Arthritis and rheumatism
    57. TANNER K; YETTRAM AL; LOEFFLER M; GOODIER WD; FREEMAN MAR; BONFIELD W
      IS STEM LENGTH IMPORTANT IN UNCEMENTED ENDOPROSTHESES (VOL 17, PG 291, 1995)

      Medical engineering & physics
    58. TANNER KE; YETTRAM AL; LOEFFLER M; GOODIER WD; FREEMAN MAR; BONFIELD W
      IS STEM LENGTH IMPORTANT IN UNCEMENTED ENDOPROSTHESES

      Medical engineering & physics
    59. DEHAAN G; DONTJE B; NIJHOF W; LOEFFLER M
      EFFECTS OF CONTINUOUS STEM-CELL FACTOR ADMINISTRATION ON NORMAL AND ERYTHROPOIETIN-STIMULATED MURINE HEMATOPOIESIS - EXPERIMENTAL RESULTS AND MODEL ANALYSIS

      Stem cells
    60. DIEHL V; LOEFFLER M; PFREUNDSCHUH M; RUEHL U; HASENCLEVER D; NISTERSBACKES H; SIEBER M; SMITH K; TESCH H; GEILEN W; ADLER M; BARTELS H; BRANDENBURG U; DIEZLER P; DOELKEN G; ENZIAN J; FUCHS R; GASSMANN W; GERHARTZ H; HAGENAUKAMP U; HECHT T; HILLER E; HINKELBEIN H; LATHAN B; KIRCHNER H; KUEHN G; KUERTEN H; LOOS U; MAKOSKI B; OERTEL W; PETSCH S; PFAB R; PFLUEGER H; PLANKER M; ROHLOFF R; SACK H; SAMANDARI S; SAUER R; SCHALK K; SCHMITZ G; SCHOPPE W; SCHWIEDER G; SZEPESI S; TEICHMANN J; WILHELMY W; WORST P; FISCHER R; GEORGII A; HUEBNER K; SCHWARZE EW
      FURTHER CHEMOTHERAPY VERSUS LOW-DOSE INVOLVED-FIELD RADIOTHERAPY AS CONSOLIDATION OF COMPLETE REMISSION AFTER 6 CYCLES OF ALTERNATING CHEMOTHERAPY IN PATIENTS WITH ADVANCED HODGKINS-DISEASE

      Annals of oncology
    61. NIJHOF W; DEHAAN G; DONTJE B; ENGEL C; LOEFFLER M
      MAINTENANCE OF NORMAL HEMATOPOIETIC-CELL PRODUCTION DURING SIMULTANEOUS ADMINISTRATION OF CYTOTOXIC DRUGS AND HEMATOPOIETIC GROWTH-FACTORS TO MICE

      Experimental hematology
    62. DEHAAN G; DONTJE B; ENGEL C; LOEFFLER M; NIJHOF W
      GROWTH FACTOR-INDUCED IN-VIVO EXPANSION OF PRIMITIVE CELLS PROTECTS AGAINST LETHAL DOSE OF 5-FLUOROURACIL

      Experimental hematology
    63. LOEFFLER M; SCHMITZ S; FRANKE H; ENGEL C; DEHAAN G; NIJHOF W
      MATHEMATICAL-MODELS OF CSF DRIVEN HUMAN AND MURINE GRANULOPOIESIS

      Experimental hematology
    64. DEHAAN G; DONTJE B; ENGEL C; LOEFFLER M; NIJHOF W
      BEHAVIOR OF MURINE HEMATOPOIETIC STEM-CELL SUBSETS DURING PROLONGED GRANULOCYTE-COLONY-STIMULATING FACTOR ADMINISTRATION

      Experimental hematology
    65. FRANKE H; LOEFFLER M; SCHMITZ S
      A MODEL EXPLANATION OF THE CONTRASTING EFFECTS OF RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (CSF) AND GRANULOCYTE CSF TREATMENT ON THE BLOOD-ELEMENTS IN HUMAN CYCLIC NEUTROPENIA

      Experimental hematology
    66. DEHAAN G; ENGEL C; DONTJE B; LOEFFLER M; NIJHOF W
      HEMOTOXICITY BY PROLONGED ETOPOSIDE ADMINISTRATION TO MICE CAN BE PREVENTED BY SIMULTANEOUS GROWTH-FACTOR THERAPY

      Cancer research
    67. DEHAAN G; DONTJE B; ENGEL C; LOEFFLER M; NIJHOF W
      IN-VIVO EFFECTS OF INTERLEUKIN-11 AND STEM-CELL FACTOR IN COMBINATIONWITH ERYTHROPOIETIN IN THE REGULATION OF ERYTHROPOIESIS

      British Journal of Haematology
    68. DEHAAN G; DONTJE B; ENGEL C; LOEFFLER M; NIJHOF W
      THE KINETICS OF MURINE HEMATOPOIETIC STEM-CELLS IN-VIVO IN RESPONSE TO PROLONGED INCREASED MATURE BLOOD-CELL PRODUCTION INDUCED BY GRANULOCYTE-COLONY-STIMULATING FACTOR

      Blood
    69. DREGER P; KLOSS M; PETERSEN B; HAFERLACH T; LOFFLER H; LOEFFLER M; SCHMITZ N
      AUTOLOGOUS PROGENITOR-CELL TRANSPLANTATION - PRIOR EXPOSURE TO STEM CELL-TOXIC DRUGS DETERMINES YIELD AND ENGRAFTMENT OF PERIPHERAL-BLOOD PROGENITOR-CELL BUT NOT OF BONE-MARROW GRAFTS

      Blood
    70. SCHMITZ S; FRANKE H; LOEFFLER M; WICHMANN HE; DIEHL V
      REDUCED VARIANCE OF BONE-MARROW TRANSIT-TIME OF GRANULOPOIESIS - A POSSIBLE PATHOMECHANISM OF HUMAN CYCLIC NEUTROPENIA

      Cell proliferation
    71. PFREUNDSCHUH MG; RUEFFER U; LATHAN B; SCHMITZ N; BROSTEANU O; HASENCLEVER D; HAAS R; KIRCHNER H; KOCH P; KUSE R; LOEFFLER M; DIEHL V
      DEXA-BEAM IN PATIENTS WITH HODGKINS-DISEASE REFRACTORY TO MULTIDRUG CHEMOTHERAPY REGIMENS - A TRIAL OF THE GERMAN HODGKINS-DISEASE STUDY-GROUP

      Journal of clinical oncology
    72. LI YQ; ROBERTS SA; PAULUS U; LOEFFLER M; POTTEN CS
      THE CRYPT CYCLE IN MOUSE SMALL-INTESTINAL EPITHELIUM

      Journal of Cell Science
    73. DEHAAN G; ENGEL C; DONTJE B; NIJHOF W; LOEFFLER M
      MUTUAL INHIBITION OF MURINE ERYTHROPOIESIS AND GRANULOPOIESIS DURING COMBINED ERYTHROPOIETIN, GRANULOCYTE-COLONY-STIMULATING FACTOR, AND STEM-CELL FACTOR ADMINISTRATION - IN-VIVO INTERACTIONS AND DOSE-RESPONSESURFACES

      Blood
    74. PFREUNDSCHUH M; HASENCLEVER D; LOEFFLER M; EHNINGER G; KIRCHNER H; KOCH P; SCHMITZ N; LATHAN B; RUEFFER U; SEXTRO M; FRANKLIN J; TESCH H; DIEHL V
      WHAT INCREMENT OF CHEMOTHERAPY DOSE CAN BE ACHIEVED BY GM-CSF SUPPORTVS PLACEBO - RESULTS OF A RANDOMIZED DOUBLE-BLIND DOSEFINDING TRIAL ESCALATING ETOPOSIDE WITHIN THE DEXABEAM REGIMEN IN HODGKINS LYMPHOMA

      Blood
    75. LOEFFLER M; RUHL U; HASENCLEVER D; PFREUNDSCHUH M; KIRCHNER H; EMMINGER H; HILLER E; GERHARTZ H; ROHLOFF R; SCHOPPE W; KURTEN H; PFLUGER H; PFAB R; ADLER M; DUHMKE E; SIEBER M; FRANKLIN J; SMITH K; NISTERSBACKES H; TESCH H; DIEHL V
      IRRADIATION WITH 20, 30 OR 40 GY IS EQUALLY EFFECTIVE IN NONBULKY AREAS AFTER 2 DOUBLE CYCLES OF COPP-ABVD POLY-CHEMOTHERAPY IN INTERMEDIATE STAGE HODGKINS-DISEASE

      Blood
    76. DEHAAN G; DONTJE B; LOEFFLER M; NIJHOF W
      THE EFFECT OF STEM-CELL FACTOR ON NORMAL AND EPO-STIMULATED MURINE HEMATOPOIESIS

      Experimental hematology
    77. NIJHOF W; GORIS H; DONTJE B; DRESZ J; LOEFFLER M
      OPTIMAL ERYTHROID CELL PRODUCTION DURING ERYTHROPOIETIN TREATMENT OF MICE OCCURS BY EXPLOITING THE SPLENIC MICROENVIRONMENT

      Experimental hematology
    78. PAULUS U; LOEFFLER M; ZEIDLER J; OWEN G; POTTEN CS
      THE DIFFERENTIATION AND LINEAGE DEVELOPMENT OF GOBLET CELLS IN THE MURINE SMALL-INTESTINAL CRYPT - EXPERIMENTAL AND MODELING STUDIES

      Journal of Cell Science
    79. DEHAAN G; DONTJE B; LOEFFLER M; NIJHOF W
      MICROENVIRONMENTALLY DEPENDENT EFFECTS ON MURINE HEMATOPOIESIS BY A PROLONGED INTERLEUKIN-1 TREATMENT

      British Journal of Haematology
    80. DEHAAN G; DONTJE B; LOEFFLER M; NIJHOF W
      SCF TREATMENT PREVENTS THE MUTUAL INHIBITION OF GRANULOPOIESIS AND ERYTHROPOIESIS, INDUCED BY EPO AND G-CSF

      Blood


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/08/20 alle ore 16:46:59